SUNNYVALE, Calif., Aug. 4, 2017 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that the first studies
validating the benefits of the leading-edge Radixact™ System were
presented at the 59th Annual Meeting of the American Association of
Physicists in Medicine (AAPM) held in Denver, Colorado, July
30 through August 3, 2017. This smart radiation therapy
system represents the next generation in TomoTherapy® treatment
delivery, significantly increasing treatment speed and ease of use.
The Radixact System enables clinicians to treat a wide range of
cancer cases, from initial plan delivery to adaptive therapy to
complex retreatments, with precision and increased efficiency.
Research highlights include:
Faster planning and reduced treatment time
- A study evaluated the performance of the Radixact System based
on a comparison of treatment plans developed for this system and
the TomoHDA™ System. Treatment plans were created using the VoLO™
Planning Solution for the TomoHDA technology, then recreated using
the Accuray Precision™ Treatment Planning System (TPS) for the
Radixact System. Developing optimal plans using the Accuray
Precision TPS was much faster, and the treatment beam-on time was
reduced by up to 50% while maintaining the excellent plan quality.
Researchers at the Miami Cancer Institute in Miami, Florida and Accuray Incorporated
conducted the research.
Proven image quality and stability
- The first clinical assessment of Radixact low-dose fan beam
MVCT image guidance found there was no statistically significant
difference in the noise, uniformity, and Hounsfield units (HU)
stability over the three-month evaluation period, demonstrating the
strength of the System's MVCT image quality and its potential value
for dose calculation. Clinicians at the Miami Cancer Institute team
conducted the research.
Easy installation
- Radixact and TomoTherapy System dosimetric beam characteristics
were compared over a six-month period. Radixact data were within
the specifications established for the TomoTherapy System and
showed a good agreement with the beam model. These results indicate
that the beam commissioning process will be straightforward for the
Radixact System. Researchers at Miami Cancer Institute and Accuray
conducted the study.
The future of radiation therapy
- Two studies demonstrated the feasibility of real-time motion
management leveraging the TomoTherapy System's one-of-a-kind
helical delivery capabilities.
-
- Accuray researchers investigated the potential for adapting the
CyberKnife® System's unique Synchrony® Respiratory Tracking System
to an experimental TomoTherapy System. The study showed
Synchrony-like real-time respiratory motion management is
technically feasible using TomoTherapy technology, enabling a high
level of accuracy when delivering dose to tumors that move with
respiration.
- The dosimetric impact of using real-time primary jaw/multileaf
collimator (MLC) compensation approaches to mitigate motion during
TomoHelical™ delivery was analyzed by a team of researchers from
the University of Wisconsin, Madison
and Accuray. Dose was calculated for treatment plans assuming 1) no
motion, 2) respiratory motion, and 3) respiratory motion
compensated by adjusting the jaw and MLC position during delivery.
The team found that a jaw and MLC compensation approach mitigated
the large difference between planned and delivered dose caused by
motion, thus enabling reductions in margin.
"The data presented at this year's AAPM speak to the precision,
accuracy and effectiveness of Accuray's entire portfolio of
radiation therapy systems," said Calvin
Maurer, Ph.D., Vice President and Chief Technology Officer
at Accuray. "The Radixact™ System findings reinforce what customers
are experiencing in their day-to-day practice and demonstrate its
value to the radiation oncology team and their patients. In
partnership with our customers we are continuing to develop
clinically relevant technological advances such as the Radixact
System, PreciseART™ Adaptive Solution and PreciseRTX™ Retreatment
Option, which make it easier for clinicians to provide patients
with the best possible treatment for them at each stage of their
cancer treatment journey."
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, future developments of our
technologies and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 28, 2015, the company's
reports on Form 10-Q, filed on November 5,
2015 and February 1, 2016 and
April 29, 2016, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly,
investors should not put undue reliance on any forward-looking
statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Danielle Sullivan
MSLGROUP
+1 (781) 684-6680
Danielle.sullivan@mslgroup.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/first-radixact-system-research-results-presented-at-the-american-association-of-physicists-in-medicine-annual-meeting-300499665.html
SOURCE Accuray Incorporated